FIG. 6.

Antiviral activities, tested with herpes simplex virus type 1, of reduced and oxidized wild-type hBD1 with different peptide concentrations (A); antiviral activities (cell, virus, and peptide at zero time) with increasing concentrations of hBD1 and hBD3 and analogs 1C, 1N, 3C, 3N, and 3I (B); and antiviral activities of peptides hBD1 and hBD3 and analogs 1C, 1N, 3C, 3N, and 3I (20 μM) after different treatments (see also Materials and Methods): coexposure, cell, virus, and peptide at time zero; virus pretreatment, virus and peptide before cell infection; and cell preexposure, cell and peptide before virus infection (C). Error bars show the SDs of experiments performed in triplicate.